Search results
Results from the WOW.Com Content Network
In 2018, [22] and 2019, [23] Aurobindo Pharma USA recalled tablets containing valsartan due to the detection of N-Nitrosodiethylamine (NDEA) which is a probable human carcinogen. In November 2019, Aurobindo Pharma USA recalled ranitidine tablets, capsules, and syrup due to the detection of unacceptable levels of N-nitrosodimethylamine (NDMA). [24]
Alogliptin, sold under the brand names Nesina and Vipidia, [2] [3] is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. [4] Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. [1]
Zinc sulfide (or zinc sulphide) is an inorganic compound with the chemical formula of ZnS. This is the main form of zinc found in nature, where it mainly occurs as the mineral sphalerite.
It was alleged that the company had increased the price of hydrocortisone tablets by more than 12,000% over the course of eight years. It sold about 943,000 packets of the tablets to the National Health Service in 2015. 10 mg hydrocortisone tablets,, which were sold for 79p in April 2008, cost £88 per pack by March 2016; 20 mg hydrocortisone ...
More than 2,000 Amazon shoppers swear by this whitening pen. Right now, it's more than half off at just $17.
Torrent Pharmaceuticals was established in 1959 by U. N. Mehta as Trinity Laboratories. It was renamed as Torrent Pharmaceuticals in 1971. [5]In 1997, Torrent Pharma and Sanofi established a 50:50 joint venture called Sanofi Torrent for selling Torrent Pharma's products. [6]
This is a list of 5α-reductase inhibitors (5α-RIs), drugs which inhibit one or more isoforms of the enzyme 5α-reductase.This enzyme is responsible for the conversion of the androgen hormone testosterone into the more potent dihydrotestosterone (DHT) and is essential for the production of neurosteroids like allopregnanolone, tetrahydrodeoxycorticosterone (THDOC), and 3α-androstanediol from ...
In 2023, more than five million Americans 12 and older reported a "prescription use disorder" within the past year, according to the Centers for Disease Control and Prevention (CDC).